Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 20/100

ADMA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating ADMA Biologics, Inc. for potential violations of federal securities laws on behalf of its stockholders. The investigation was prompted by a report from Culper Research, which claims that ADMA's reported growth may be misleading due to illicit business practices. After the report's release, ADMA's stock experienced a notable decline, falling by over 16%. The law firm urges affected investors to reach out regarding their legal options.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA is under investigation for potential violations of federal securities laws.
  • A report alleges that ADMA's growth claims are exaggerated due to channel stuffing.
  • Following the investigation news, ADMA's stock price dropped significantly.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in ADMA and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) on behalf of ADMA stockholders. Our investigation concerns whether ADMA has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On March 24, 2026, Culper Research published a short report on ADMA, alleging that "ADMA's reported growth is a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor" and "estimat[ing] that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported."
Following publication of the Culper report, ADMA's stock price fell $2.26 per share, or 16.63%, to close at $11.33 per share on March 24, 2026.
If you purchased or otherwise acquired ADMA shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

How can ADMA investors contact for legal options?

Investors can reach out to Brandon Walker or Melissa Fortunato at (212) 355-4648.

What triggered the investigation into ADMA Biologics?

Culper Research released a report alleging ADMA's revenue growth was deceptive.

What was the impact of the report on ADMA's stock price?

ADMA's stock dropped $2.26, or 16.63%, closing at $11.33 per share.

What does Bragar Eagel & Squire specialize in?

They represent investors in securities litigation and individual consumer protection cases.

Is there a cost to consult with Bragar Eagel & Squire?

There is no cost or obligation for investors to consult with the firm.

Last updated: Mar 27, 2026